Neuromuscular blocking agents (NMBAs) are used to induce total paralysis to permit intubation and muscle relaxation during surgery or in ventilated patients. NMBAs permit a very rapid induction of neuromuscular blockade at the onset of use, and the reversal agent will provide for more rapid reversal of the neuromuscular blockade. We are developing an intermediate-acting NMBA, RP1000, an ultrashort-acting NMBA, RP2000, and a reversal agent specific to our NMBAs. The table below summarizes the predicted onset and duration of action for each NMBA based on currently available data, as well as the development status of each NMBA:

Compound Onset Time Duration of Action Status
RP1000 Rapid Intermediate-acting Phase I
RP2000 Rapid Ultra-short acting Pre-IND

In animal models, the proprietary reversal agent acts quickly by chemical reaction to reverse the neuromuscular blockade. We believe that the NMBAs can reduce the time required for induction of anesthesia and the reversal agent can reduce the time needed to recover from NMBA dosing post-procedure, while potentially enhancing patient safety and resulting in cost savings for the hospital or another provider.

We have a worldwide, exclusive license to the NMBAs and the related reversal agent from Cornell.